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Worsening of symptoms and signs leading to hospital admission is an important event for patients with heart 
failure (HF), because, not only is it an unpleasant experience, 
but it is also a marker of heightened subsequent risk of read-
mission and death.1,2 Hospital admissions also place an eco-
nomic burden on patients and their families or caregivers, 
Background—Many episodes of worsening of heart failure (HF) are treated by increasing oral therapy or temporary 
intravenous treatment in the community or emergency department (ED), without hospital admission. We studied the 
frequency and prognostic importance of these episodes of worsening in the Prospective Comparison of ARNI (angiotensin-
receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Impact on Global 
Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Methods and Results—Outpatient intensification of HF therapy was added to an expanded composite outcome with ED 
visits, HF hospitalizations, and cardiovascular deaths. In an examination of first nonfatal events, 361 of 8399 patients 
(4.3%) had outpatient intensification of HF therapy without a subsequent event (ie, ED visit/HF hospitalizations) within 
30 days; 78 of 8399 (1.0%) had an ED visit without previous outpatient intensification of HF therapy or a subsequent 
event within 30 days; and 1107 of 8399 (13.2%) had HF hospitalizations without a preceding event. The risk of death 
(in comparison with no-event patients) was similar after each manifestation of worsening: outpatient intensification of 
HF therapy (hazard ratio, 4.8; 95% confidence interval, 3.9–5.9); ED visit (hazard ratio, 4.5; 95% confidence interval, 
3.0–6.7); HF hospitalizations (hazard ratio, 5.9; 95% confidence interval, 5.2–6.6). The expanded composite added 14% 
more events and shortened time to accrual of a fixed number of events. The benefit of sacubitril/valsartan over enalapril 
was similar to the primary outcome for the expanded composite (hazard ratio, 0.79; 95% confidence interval, 0.73–0.86) 
and was consistent across the components of the latter.
Conclusions—Focusing only on HF hospitalizations underestimates the frequency of worsening and the serious implications 
of all manifestations of worsening. For clinical trials conducted in an era of heightened efforts to avoid HF hospitalizations, 
inclusion of episodes of outpatient treatment intensification (and ED visits) in a composite outcome adds an important 
number of events and shortens the time taken to accrue a target number of end points in an event-driven trial.
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health services, and society more generally.3,4 For these rea-
sons, HF hospitalization has long been considered an impor-
tant end point in clinical trials, and, more recently, it has 
become a measure of the quality of care in the United States 
with linkage of reimbursement to readmission rates within 30 
days of discharge.5–9 Many episodes of worsening of HF are, 
however, treated by augmentation of oral therapy in the com-
munity or even the use of short-term intravenous treatment. 
Some episodes may also lead to an emergency department 
(ED) visit without subsequent admission to the hospital.10–13 
Management of HF in the community or in non–ward-based 
hospital settings has also been encouraged recently by many 
organizations as a result of the reimbursement changes 
mentioned above.6–9,14 Little is known, however, about the 
frequency and prognostic importance of such nonhospital-
ized episodes of worsening.15 We have studied the occur-
rence and significance of these episodes in the Prospective 
Comparison of ARNI (angiotensin-receptor-neprilysin 
inhibitor) with ACEI (angiotensin-converting enzyme inhibi-
tor) to Determine Impact on Global Mortality and Morbidity 
in Heart Failure Trial (PARADIGM-HF).16–18 We have also 
investigated the potential value of such events in an expanded 
composite outcome that might be of use as an end point in 
future clinical trials.
Clinical Perspective on p 2262
Methods
Patients
The background and results of PARADIGM-HF (www.clinicaltrials.
gov. identifier: NCT01035255) have been published.16–18 The Ethics 
Committee of each of the 1043 participating institutions (in 47 coun-
tries) approved the protocol. All patients gave written, informed con-
sent. In brief, PARADIGM-HF was a randomized, double-blind, and 
prospective comparison of the angiotensin-receptor-neprilysin inhibi-
tor sacubitril/valsartan (formerly known as LCZ696) with enalapril 
in patients with chronic HF. Eligibility requirements at screening 
included an age of at least 18 years, New York Heart Association 
functional class II to IV symptoms, and a left ventricular ejection 
fraction of ≤40% and guideline-recommended therapy.
Trial Outcomes
The primary outcome of PARADIGM-HF was the composite of 
cardiovascular death or HF hospitalization. Additional prespecified 
exploratory end points included ED visits and outpatient intensifica-
tion of HF therapy, collected by means of check box questions (yes/
no) asked at each study visit. Three questions were asked in relation 
to outpatient intensification of HF therapy: was the dose of diuretics 
increased and sustained for a month (yes/no), was intravenous treat-
ment given for HF (yes/no), or was a new drug added for the treat-
ment of worsening HF (yes/no)? If any of these were answered in the 
affirmative the patients were prospectively considered to have had 
outpatient intensification of HF therapy.
We examined the characteristics of and subsequent survival of 
patients having a first event of each type and survival after each event 
type. In this analysis, if patients had an ED visit or were hospitalized 
within 30 days after intensification of therapy, they were classified 
as either an ED visit or HF hospitalization, respectively. If patients 
were hospitalized within 30 days after an ED visit, they were clas-
sified as a HF hospitalization and not an ED visit. The reference 
group consisted of patients who had none of these events during 
the trial (no-event group). We also used this analysis to estimate 
the reduction in time taken to accrue a certain number of composite 
events, comparing the expanded composite (cardiovascular death, 
HF hospitalization, ED visit, or outpatient intensification of therapy) 
with the narrowest (ie, the primary composite end point of cardio-
vascular death or HF hospitalization) using a time-to-first event 
analysis. In a sensitivity analysis, we used 7 instead of 30 days as the 
interval separating events.
To examine the number of unique events added by considering 
outpatient intensification of therapy and ED visits, we also catego-
rized patients into 3 mutually exclusive groups for a first nonfatal 
event (ie, without any of the listed nonfatal events preceding the 
event of interest) or cardiovascular death: those having outpatient 
intensification of HF therapy (without a subsequent ED visit or HF 
hospitalization), those having an ED visit (without a subsequent HF 
hospitalization), and those having a HF hospitalization as their first 
nonfatal event.
We also examined the effect of sacubitril/valsartan in com-
parison with enalapril on the expanded composite outcome and its 
components.
Statistical Analysis
Baseline characteristics were compared by using the Kruskal-
Wallis test for continuous variables and the χ2 test for categorical 
variables. The association between a first event and subsequent 
mortality was evaluated with the use of Kaplan–Meier estimates 
and examined in a Cox regression model with the no-event group 
used as reference. The relative hazard of death following a first 
event was examined in a Cox proportional hazards model where 
an indicator of a patient’s first event type was entered into the 
model as a time-updated covariate (with follow-up time start-
ing at randomization) and adjusted for the effect of randomized 
therapy and region and then with the addition of the following 
baseline variables: age, sex, race, systolic blood pressure, heart 
rate, body mass index , serum creatinine, left ventricular ejection 
fraction, N-terminal pro-B-type natriuretic peptide, New York 
Heart Association class, ischemic etiology, hypertension, diabe-
tes mellitus, atrial fibrillation, previous HF, myocardial infarction, 
stroke, previous implantable cardioverter-defibrillator, and cardiac 
resynchronization therapy. Hazard ratios (HRs), 95% confidence 
intervals (CIs), and 2-sided P values were calculated with the use 
of the Cox models. All analyses were performed using Stata ver-
sion 14 (Stata Corp. College Station, TX). A P value of <0.05 was 
considered significant.
Results
Of the 8399 patients randomized, 1124 (13.4%) had outpatient 
intensification of therapy, 250 (3.0%) had an ED visit, 1195 
(14.2%) were hospitalized for worsening HF, 1251 (14.9%) 
died of a cardiovascular cause, and 1546 (18.4%) died of any 
cause.
Among all randomized patients, 763 (9.1%) died of a car-
diovascular cause without previous worsening HF hospitaliza-
tion, ED visit, or intensification of therapy.
In an examination of first nonfatal events, 361 patients 
(4.3%) had intensification of therapy without a subsequent 
ED visit, hospital admission for HF, or cardiovascular death 
within 30 days; 78 (1.0%) had an ED visit but no previous 
intensification of therapy or subsequent hospital admission 
for worsening HF or cardiovascular death within 30 days; 
and 1107 patients (13.2%) had worsening HF requiring hos-
pitalization without a preceding ED visit or intensification 
of therapy.
Examining mutually exclusive first nonfatal events, 
223 patients (62% of 361) having intensification of therapy 
and 52 patients (67% of 78) experiencing an ED visit did 
not have a subsequent nonfatal HF event during the trial 
period or die of a cardiovascular cause. The numbers not 
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Table 1. Baseline Characteristics of Patients With Different First Manifestations of Heart Failure Worsening, or None, or 
Experiencing Cardiovascular Death
None of the Events
Hospitalization  
for HF
Emergency  
Department Visit for HF
Intensification of HF 
Therapy Cardiovascular Death P Value
n (%) 6090 (73) 1107 (13) 78 (1) 361 (4) 763 (9)
Age, year 63±11 64±11 66±12 65±11 64±12 <0.001
Sex (female), n (%) 1410 (23) 212 (19) 16 (21) 56 (16) 138 (18) <0.001
Race, n (%)
  White 4016 (66) 749 (68) 43 (55) 287 (80) 449 (60) <0.001
  Black 285 (5) 82 (7) 6 (8) 17 (5) 38 (5)
  Asian 1097 (18) 188 (17) 18 (23) 28 (8) 178 (23)
  Other 692 (11) 88 (8) 11 (14) 29 (8) 98 (13)
Region, n (%)
  North America 365 (6) 124 (11) 13 (17) 73 (20) 27 (4) <0.001
  Latin America 1091 (18) 142 (13) 13 (17) 39 (11) 148 (19)
  Western Europe and other 1516 (25) 275 (25) 13 (17) 111 (31) 136 (18)
  Central Europe 2028 (33) 384 (35) 21 (27) 110 (31) 283 (37)
  Asia 1090 (18) 182 (16) 18 (23) 28 (8) 169 (22)
Systolic blood pressure, mm Hg 122±15 121±16 118±14 120±16 122±16 0.084
Heart rate, beats/min 72±12 74±13 74±13 72±13 73±12 <0.001
Body mass index, kg/m2 28±5 29±6 27±6 29±6 27±6 <0.001
Serum creatinine, mg/dL 1.1±0.3 1.2±0.3 1.2±0.3 1.2±0.3 1.2±0.3 <0.001
Clinical features of heart failure
  Left ventricular ejection fraction, % 30±6 29±7 28±7 30±6 29±7 <0.001
  Median BNP, pg/mL (IQR) 227 (142–407) 365 (195–723) 290 (167–528) 286 (176–560) 369 (206–689) <0.001
  Median NT-proBNP, pg/mL (IQR) 1438 (819–2737) 2367 (1208–5154) 1894 (1103–3319) 1923 (1047–3722) 2456 (1260–5189) <0.001
NYHA functional class, n (%)
  I 309 (5) 33 (3) 7 (9) 11 (3) 29 (4) <0.001
  II 4399 (72) 736 (67) 50 (64) 249 (69) 485 (64)
  III 1332 (22) 322 (29) 21 (26) 100 (28) 243 (32)
  IV 38 (0.6) 15 (1.4) 0 (0) 1 (0.3) 6 (0.8)
Ischemic etiology, n (%) 3593 (59) 669 (60) 44 (56) 227 (63) 503 (66) 0.004
Medical history, n (%)
  Hypertension 4252 (70) 824 (74) 59 (76) 268 (74) 537 (70) 0.012
  Diabetes mellitus 1939 (32) 492 (44) 36 (46) 162 (45) 278 (36) <0.001
  Atrial fibrillation 2123 (35) 484 (44) 34 (44) 163 (45) 287 (38) <0.001
  Previous heart failure hospitalization 3663 (60) 822 (74) 53 (68) 262 (73) 474 (62) <0.001
  Myocardial infarction 2544 (42) 521 (47) 27 (35) 182 (50) 360 (47) <0.001
  Stroke 479 (8) 115 (10) 12 (15) 43 (12) 76 (10) 0.001
Treatment at randomization, n (%)
  Previous use of ACE inhibitor 4744 (78) 853 (77) 60 (77) 288 (80) 587 (77) 0.814
  Previous use of ARB 1362 (22) 259 (23) 19 (24) 75 (21) 177 (23) 0.817
  Diuretics 4769 (78) 979 (88) 63 (81) 307 (85) 620 (81) <0.001
  Digitalis 1755 (29) 381 (34) 27 (35) 110 (31) 266 (35) <0.001
  β-Blocker 5700 (94) 1013 (92) 69 (89) 338 (94) 691 (91) 0.002
  Mineralocorticoid antagonist 3390 (56) 634 (57) 39 (50) 189 (52) 419 (55) 0.414
  Implantable cardioverter-defibrillator 840 (14) 230 (21) 15 (19) 97 (27) 61 (8) <0.001
  Cardiac resynchronization therapy 383 (6) 110 (10) 7 (9) 48 (13) 26 (3) <0.001
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; HF, heart failure; IQR, interquartile range; NT-
proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association.
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experiencing a nonfatal HF event or dying of any cause were 
203 (56% of 361) and 48 (62% of 78) for those having inten-
sification of therapy and ED visits, respectively. Therefore, 
these 2 outcomes added 278 unique events (13.7%) to the 
2031 primary composite end points (cardiovascular death or 
HF hospitalization) accrued in PARADIGM-HF.
Baseline Characteristics
The baseline characteristics of patients with the different first 
manifestations of HF worsening, experiencing cardiovascular 
death, or having no event are shown in Table 1. Patients with 
any manifestation of worsening were older, less likely to be 
female, and more likely to have comorbidity. Patients with 
any manifestation of worsening also had higher B-type natri-
uretic peptide levels, had a worse New York Heart Association 
functional class, were more commonly treated with diuretics, 
digoxin, a defibrillating device, and cardiac resynchronization 
therapy, and more frequently had a history of prerandomiza-
tion HF hospitalization.
Different Manifestations of Worsening and 
Subsequent Survival
Figure 1 shows the rate of death and Table 2 shows the unad-
justed and adjusted risks of death subsequent to intensification 
of therapy, an ED visit, or a HF hospitalization, in compari-
son with patients who did not experience any manifestation 
of worsening. Overall, 14% of patients without any report of 
worsening died during the trial. The proportion dying was 
32%, 31%, and 37%, respectively, for those having intensifi-
cation of therapy, experiencing an ED visit, or being admitted 
to hospital with worsening HF. Most deaths were attributed to 
cardiovascular causes.
The risk of death (in comparison with no-event patients 
after adjustment for treatment and region only) was similar 
after each of the 3 manifestations of worsening: intensifica-
tion of therapy (HR, 5.2; 95% CI, 4.2–6.3); ED visit (HR, 
4.5; 95% CI, 3.0–6.7); and hospitalization for worsening HF 
(HR, 6.1; 95% CI, 5.4–6.8). Even after adjustment, the risk of 
death remained 3 to 5 times higher in patients experiencing 
some manifestation of worsening, in comparison with those 
who did not. When those patients who had only either a hos-
pitalization for HF, ED visit, or intensification of therapy were 
analyzed, ie, they experienced that event type only, the asso-
ciations between each of the event types and mortality were 
unchanged (Table 2).
Using a 7-day rather than 30-day interval between events 
(to define separate events) did not change the results (Table I 
in the online-only Data Supplement).
We conducted a sensitivity analysis by baseline diuretic 
status. In the patients not taking a diuretic (n=1661) at base-
line, the risk of death was higher in those who started a 
diuretic during the trial (n=443; all-cause mortality=20.5%) 
in comparison with those who did not start a diuretic during 
the trial (n=1218; all-cause mortality=12.6%). Of those tak-
ing a diuretic at baseline, the risk of death in those who were 
taking the equivalent of <40 mg of furosemide at baseline 
was 16.4% and, in those taking ≥40 mg furosemide equiva-
lent, the risk was 21.0%. The association between each of 
the outcomes (HF hospitalization, ED visit for HF, or inten-
sification of therapy for HF) and the risk of all-cause mortal-
ity was similar regardless of the baseline dose of furosemide 
equivalent (Table II in the online-only Data Supplement). Of 
those who experienced an intensification of HF therapy that 
was attributable to an increase in diuretic dose for >1 month, 
the risk of death was higher in those who had an increase 
in dose that was ≥40 mg of furosemide equivalent in com-
parison with <40 mg furosemide equivalent (Table III in the 
online-only Data Supplement).
We also examined which medications were added for the 
treatment of worsening HF (n=62). This was a diuretic in 23 
(37%), an mineralocorticoid receptor antagonist in 17 (27%), 
a β-blocker in 9 (15%), an angiotensin-converting enzyme 
inhibitor/angiotensin receptor blocker in 8 (13%), and other 
drugs (digoxin in 2; unspecified in 3) in 5 (8%).
Figure 1. Mortality (%) after a first event or in patients with no event. CV indicates cardiovascular.
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The association between each manifestation of wors-
ening HF and subsequent all-cause mortality was highest 
for intravenous treatment given for HF: dose of diuretics 
increased and sustained for a month (HR, 3.2; 95% CI, 
2.2–5.0), intravenous treatment for HF (HR, 7.3; 95% CI, 
5.5–9.6), and a new drug added for the treatment of worsening 
HF (HR, 3.7; 95% CI, 2.3–5.8).
Expanded Composite Outcomes and Time to 
Accrual of a Target Number of Events
Figure 2 shows the impact of adding intensification of therapy 
and ED visits to the primary composite outcome (cardiovascu-
lar death or HF hospitalization) of PARADIGM-HF. As can be 
seen at 1, 2, and 3 years of follow-up, an additional 177, 248, 
and 269 patients, respectively, had experienced a first event 
contributing to the expanded composite outcome in compar-
ison with the primary end point, an increment in events of 
≈14% overall. The 1- and 2-year Kaplan–Meier event rates for 
the primary end point were 14.2% and 24.0%, respectively, 
in comparison with 16.5% and 27.5%, respectively, for the 
expanded composite. The time taken to accrue 1000 patients 
with an event using the primary end point was 11 months 
(338 days) in comparison with 9 months (280 days) for the 
expanded composite.
Effect of Sacubitril/Valsartan on the Primary 
Composite Outcome and Expanded Composite
Figure 3 shows the effect of sacubitril/valsartan on the primary 
composite outcome of PARADIGM-HF, and the expanded 
composite outcome and the components of each of these, as 
well.
Sacubitril/valsartan was superior to enalapril in reducing 
the risk of the primary composite outcome (HR, 0.80; 95% 
CI, 0.73–0.87), death from cardiovascular causes (HR, 0.80; 
95% CI, 0.71–0.89), and hospitalization for HF (HR, 0.79; 
95% CI, 0.71–0.89).
As can be seen from Figure 4, the benefit of sacubitril/val-
sartan over enalapril was similar for the expanded composite 
(HR, 0.79; 95% CI, 0.73–0.86) and the effect of sacubitril/val-
sartan was consistent in relation to the additional components 
of this expanded composite. This effect of sacubitril/valsartan 
compared with enalapril on the expanded composite was also 
consistent across all subgroups, eg, age, sex, race, region, and 
medical history (data not shown).
Discussion
Our findings are relevant to both clinical practice and the 
conduct of future clinical trials in HF with reduced ejection 
fraction.
As expected, we found that worsening leading to out-
patient intensification of medical therapy is common in 
patients with HF with reduced ejection fraction, but more 
surprisingly was associated with an elevation in the risk 
of subsequent death similar to that seen following hospital 
admission. Focusing only on HF hospitalization therefore 
underestimates the frequency of clinical worsening and fails 
to recognize that all manifestations of worsening have such 
serious implications.
For clinical trials conducted in an era of heightened efforts 
to avoid hospitalization in patients with HF, inclusion of epi-
sodes of outpatient intensification of medical therapy (and ED 
visits) in a composite outcome adds an important number of 
events (an increment of 14% in PARADIGM-HF) and would 
shorten the time taken to accrue a target number of end points 
in an event-driven trial. Because sacubitril/valsartan had a 
consistent effect on all manifestations of worsening, the bene-
fit of sacubitril/valsartan over enalapril on the expanded com-
posite outcome was similar to that on the primary end point in 
PARADIGM-HF. Therefore, use of this expanded composite 
could have resulted in earlier termination of the trial with-
out any loss of sensitivity to the effect of the investigational 
treatment.
Although everyday clinical experience indicates that aug-
mentation of oral therapy and even supplementation with 
intravenous treatment is common in patients with HF, we have 
Table 2. Risk of All-Cause Mortality After a Hospitalization Heart Failure, Emergency Department Visit for Heart Failure, 
and Intensification of Therapy for Heart Failure Using a Cox Model With Event Type as the First Event Experienced and the 
Only Event Experienced as a Time-Updated Covariate
None of the 
Events
Hospitalization 
for HF
Emergency 
Department Visit 
for HF
Intensification of HF 
Therapy
Each event as the first event experienced in a time-updated model, hazard ratio (95% CI)
  Adjusted for randomized treatment and region 1 6.1 (5.4–6.8) 4.5 (3.0–6.7) 5.2 (4.2–6.3)
  Adjusted for randomized treatment, region, and baseline 
covariates*
1 5.3 (4.7–6.0) 3.3 (2.2–5.0) 4.6 (3.7–5.6)
Each event as the only event experienced in a time updated model, hazard ratio (95% CI)
  Adjusted for randomized treatment and region 1 5.8 (5.1–6.5) 4.1 (2.6–6.5) 4.5 (3.6–5.7)
  Adjusted for randomized treatment, region, and baseline 
covariates*
1 5.0 (4.4–5.7) 2.9 (1.9–4.6) 4.2 (3.3–5.3)
CI indicates confidence interval; and HF, heart failure.
*Adjusted for age, sex, race, systolic blood pressure, heart rate, body mass index, serum creatinine, left ventricular ejection fraction, N-terminal pro-B-type 
natriuretic peptide, New York Heart Association class, ischemic etiology, hypertension, diabetes mellitus, atrial fibrillation, previous heart failure, myocardial 
infarction, stroke, previous implantable cardioverter-defibrillator, and cardiac resynchronization therapy.
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been unable to find any report of how frequently such interven-
tions occur in usual clinical practice. Asking questions about 
augmentation of treatment at each study visit, we found that 
13.4% of patients had intensification of therapy and that two-
thirds of these episodes were followed by an ED visit or HF 
hospitalization within 30 days. However, it should be noted 
that the majority of patients in PARADIGM-HF were in New 
York Heart Association functional class I (4.6%) or II (70.5%) 
after the active run-in period, and the proportion requiring 
intensification of therapy might be much greater in patients 
with more severe symptoms at baseline. The more important 
finding is that, even if augmentation of therapy was not fol-
lowed by an ED visit or admission, it was associated with a 
4-fold higher adjusted risk of subsequent death. Therefore, 
although these episodes were identified only by investigators 
checking yes in response to questions (and were not adjudi-
cated), they were an ominous occurrence and arguably should 
be both a treatment target (to reduce their incidence) and a 
measure of outcome (eg, as part of a composite worsening end 
point). Not only were these episodes frequent and serious, but 
they were also responsive to the experimental treatment inter-
vention in PARADIGM-HF, further supporting their use in an 
expanded composite end point (see below).
By contrast, ED visits were uncommonly reported (in 3% 
of patients) and were also frequently followed by HF hospital-
ization within 30 days (in 69% of cases). We believe that our 
investigators did not report ED visits leading directly to admis-
sion to hospital as separate events (because admission was 
Figure 2. Impact of adding emergency department visits and outpatient intensification therapy as additional components of a composite 
heart failure outcome. CV indicates cardiovascular; and HF, heart failure.
Figure 3. Kaplan–Meier curves for primary end point (A) and expanded composite (B), according to treatment group. (HR and 
corresponding P value are from the Cox model adjusted for region). CI indicates confidence interval; and HR, hazard ratio.
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itself an end point). In most countries the vast majority of ED 
attendances with HF lead to admission, and discharge directly 
from the ED is very uncommon. It is likely that this explains 
the small proportion of such events in PARADIGM-HF. An 
isolated ED visit was also associated with a 4- to 5-fold higher 
subsequent mortality (in comparison with having no episode 
of worsening), and this heightened risk persisted after adjust-
ment for other prognostic variables.
From a clinical practice perspective, we believe that there 
are 2 important messages from our findings. First, intensifi-
cation of outpatient therapy should be carefully documented 
and should prompt a review of affected patients. Often the 
care of patients is shared and may be disjointed. Therapy 
may be changed by a primary care practitioner, nurse spe-
cialist, internist, or other specialist (during a hospital clinic 
attendance for another reason) or by a cardiologist. It is 
easy to overlook such changes, yet they identify a patient 
at high risk. Should there be a system in place to identify 
these changes? Such changes should prompt review of the 
patient – have all disease-modifying drugs been used (eg, 
could a mineralocorticoid receptor antagonist or digoxin 
be added)? Have all life-saving devices been considered 
(eg, cardiac resynchronization therapy and an implantable 
cardioverter-defibrillator)? Has the patient progressed to the 
point of being considered for a ventricular assist device or 
transplantation?
Our findings are potentially important from a clinical 
trials perspective as well. Although most episodes of inten-
sification of outpatient therapy and ED visits were followed 
by a HF hospitalization within 30 days, approximately one-
third were not. Therefore, expanding the primary compos-
ite outcome (HF hospitalization or cardiovascular death) 
used in PARADIGM-HF and other recent studies to include 
these additional components has 2 consequences. First, 
doing so adds unique events (an additional 14% overall). 
Second, it shortens the time to accrual of any given number 
of worsening events. This is because intensification of out-
patient therapy and ED visits often occur before and there-
fore earlier than a HF hospitalization. These effects have the 
potential to reduce sample size and duration of follow-up 
(or increase power if sample size is maintained), although 
these advantages can only be realized if the additional com-
ponents of the composite (and thus the overall expanded 
composite) are as sensitive to the effects of treatment as HF 
hospitalization and cardiovascular death are (although these 
do not always respond equally to treatment). We found that 
this was the case for sacubitril/valsartan, with a similar treat-
ment effect on all components of the expanded composite 
outcome examined, but this might not necessarily be so for 
all treatments. This expanded composite may be especially 
relevant today given the intensive efforts to reduce admis-
sions to the hospital for HF in the United States (and may 
even out the rates of worsening across geographic regions 
by including all manifestations of worsening irrespective 
of how or where they are managed). In addition, because 
event rates have declined as a result of the cumulative ben-
efit of effective treatments, trials in HF with reduced ejec-
tion fraction have required larger and larger sample sizes, 
increasing their complexity and cost and making the devel-
opment of new treatments less attractive and affordable than 
previously. The only other way to accrue sufficient events 
is to lengthen follow-up, but this too leads to higher costs 
and less precision because of treatment discontinuation and 
patient loss to follow-up. Our findings suggest that the use 
of the expanded composite described has the potential to 
reduce sample size and duration of follow-up by a mod-
est amount and we believe that its use might be considered 
in future trials. We know of only a few trials in patients 
with chronic HF and a reduced ejection fraction that used 
nonhospitalized events as part of their primary end point, 
and each required intravenous therapy as part of the defi-
nition of these events.15,19–21
 In the Valsartan Heart Failure 
Trial (Val-HeFT), administration of intravenous inotropic 
or vasodilator drugs for ≥4 hours without hospitalization 
was a component of the composite coprimary outcome.19 
Of the 1524 first events, there were only 10 nonhospital-
ized treatment events in comparison with 801 HF hospi-
talizations, 42 resuscitated cardiac arrests, and 671 deaths. 
The Multicenter Automatic Defibrillator Implantation with 
Cardiac Resynchronization trial (MADIT-CRT) included 
outpatient events requiring the use of intravenous decon-
gestive therapy.15 Of first events, 52 were outpatient events, 
331 were inpatient treatment events, and 78 were deaths. The 
smaller proportion of outpatient events in these trials pre-
sumably reflects the requirement for intravenous therapy (as 
opposed to augmented or oral or intravenous therapy) and, 
perhaps, changing practice since publication of Val-HeFT. 
The individual contribution of nonhospitalized intravenous 
therapy to the overall primary outcome was not described sep-
arately in the Comparison of Medical Therapy, Pacing, and 
Defibrillation in Heart Failure trial (COMPANION) and the 
Biventricular versus Right Ventricular Pacing in Heart Failure 
Patients with Atrioventricular Block trial (BLOCK HF).20,21
Our report has some limitations. Not all of the anal-
yses reported were prespecified. The ED visits and 
Figure 4. Effect of sacubitril/valsartan versus enalapril for 
each outcome. CV indicates cardiovascular; ED, emergency 
department; and HF, heart failure.
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intensification of oral therapy were not adjudicated 
(whereas HF hospitalizations and deaths were), and we do 
not have details of all of the drugs added to treat wors-
ening HF. For the increase in diuretic dose component of 
the intensification-of-therapy end point, we required the 
increased to be sustained for at least a month, making this 
a relatively stringent component.
In conclusion, focusing only on HF hospitalization 
underestimates the frequency of clinical worsening and 
fails to recognize that other manifestations of worsening 
seem to have serious prognostic implications. If our find-
ings are valid, they argue for a systematic approach in 
clinical practice to document episodes of nonhospitalized 
worsening, and their occurrence should prompt a review 
of affected patients. For clinical trials conducted in an era 
of heightened efforts to avoid hospitalization in patients 
with HF, inclusion of episodes of outpatient intensification 
of therapy (and ED visits) in a composite outcome adds a 
modest but important number of events and shortens the 
time taken to accrue a target number of end points in an 
event-driven trial. These additional events seem to be sensi-
tive to the actions of effective therapy, at least as demon-
strated with sacubitril/valsartan.
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CLINICAL PERSPECTIVE
In this study we examined the occurrence and significance of episodes of nonhospitalized worsening of heart failure, ie, 
those treated by augmentation of oral therapy and the use of short-term intravenous treatment in the community or emer-
gency department by using the Prospective Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with ACEI 
(angiotensin-converting enzyme inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial 
(PARADIGM-HF) database. These nonhospitalized episodes of worsening heart failure were associated with a 4- to 6-fold 
higher risk of subsequent death (in comparison with patients with no events), a risk similar to that following heart failure 
hospitalization. Adding these nonhospitalized episodes to a conventional composite of cardiovascular death or heart failure 
hospitalization increased the number of events by14% and shortened the time to accrual of a fixed number of events. The 
benefit of sacubitril/valsartan over enalapril was similar to the primary outcome for the expanded composite (hazard ratio, 
0.79; 95% confidence interval, 0.73–0.86) and was consistent across each of the components of the expanded composite. 
Focusing only on heart failure hospitalization underestimates the frequency of clinical worsening and fails to recognize 
the serious implications of other manifestations of worsening. Clinicians should consider these nonhospitalized events as a 
harbinger of poor outcomes and act accordingly. For clinical trials conducted in an era of heightened efforts to avoid hos-
pitalization in patients with heart failure, the inclusion of episodes of outpatient intensification of therapy and emergency 
department visits in a composite outcome adds an important number of events and shortens the time taken to accrue a target 
number of end points in an event-driven trial.
Go to http://cme.ahajournals.org to take the CME quiz for this article.
 by guest on June 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
PARADIGM-HF Investigators and Committees*
and John J.V. McMurray
L. Rouleau, Victor C. Shi, Karl Swedberg, Michael R. Zile, Scott D. Solomon, Milton Packer 
Naoki Okumura, Pardeep S. Jhund, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean
Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)
Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on 
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting:
Print ISSN: 0009-7322. Online ISSN: 1524-4539 
Copyright © 2016 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Circulation 
doi: 10.1161/CIRCULATIONAHA.115.020729
2016;133:2254-2262; originally published online April 20, 2016;Circulation. 
 http://circ.ahajournals.org/content/133/23/2254
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://circ.ahajournals.org/content/suppl/2016/04/20/CIRCULATIONAHA.115.020729.DC1
Data Supplement (unedited) at:
  
 http://circ.ahajournals.org//subscriptions/
is online at: Circulation  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialCirculationin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on June 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
SUPPLEMENTAL MATERIAL 
 Supplemental Table 1. Mortality (%) according to baseline diuretics dose 
 
 
No diuretic at baseline Other diuretics 
Low dose loop diuretic 
(<40mg furosemide 
equivalent*) 
High dose loop diuretic  
(≥40mg furosemide equivalent*) 
 
(N=1661) (N=1324) (N=1620) (N=3794) 
  
 
  All cause death 244 (14.7%) 239 (18.1%) 265 (16.4%) 798 (21.0%) 
CV death 199 (12.0%) 205 (15.5%) 215 (13.3%) 632 (16.7%) 
non-CV death 45 (3.1%) 34 (3.0%) 50 (3.6%) 166 (4.4%) 
  
 
  * 1mg bumetanide= 40mg furosemide and 20mg torasemide= 40mg furosemide 
 
 
 
 
 
 
 
 
Supplemental Table 2. Risk of all-cause mortality following a hospitalization heart failure, emergency department visit for heart failure, 
and intensification of therapy for heart failure using a Cox model with event type as the 1st event experienced and the only event 
experienced in a time-updated covariate according to baseline loop diuretic dose 
 
 
No event 
Heart failure  
hospitalization 
Emergency  
department visit 
Intensification  
of therapy 
Each event as the 1st event experienced in a time 
updated model (Hazard Ratio (95% CI)) 
Adjusted for randomized treatment, region and baseline 
covariates* 
    
Low dose loop diuretic (<40mg furosemide 
equivalent**) 
(N=1620) 
1 
5.7 
(4.2-7.8) 
1.6 
(0.2-11.5) 
4.1 
(2.6-6.6) 
High dose loop diuretic (≥40mg furosemide 
equivalent**) 
(N=3794) 
1 
5.0 
(4.2-5.9) 
3.6 
(2.1-6.1) 
5.4 
(4.1-7.1) 
Other diuretic 
(N=1324) 
1 
5.8 
(4.2-8.0) 
4.6 
(1.9-10.7) 
3.2 
(4.2-6.1) 
* Adjusted for: age, sex, race, systolic blood pressure, heart rate, body mass index (BMI), serum creatinine, left ventricular ejection 
fraction (LVEF), N-terminal pro-BNP (NTproBNP), New York Heart Association (NYHA) class, ischemic etiology, hypertension, 
diabetes, atrial fibrillation, prior heart failure, myocardial infarction, stroke, prior implantable cardioverter-defibrillator, and cardiac 
resynchronization therapy. 
** 1mg bumetanide= 40mg furosemide and 20mg torasemide= 40mg furosemide 
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